secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2026-08-06T12:15:17+00:00
Accession:  0001193125-26-336864
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus reports Q2 net loss of $35M; cash $117.9M; FDA clearance for CRB-701 registrational study
--------------------------------------------------------------------------------

- Net loss of $35.0M ($1.81 per share) vs $17.7M ($1.44) in Q2 2025; operating expenses rose to $36.2M including $10M milestone payment.
- Cash and investments $117.9M as of June 30, 2026, expected to fund operations into 2028.
- FDA cleared TEMPO-1 registrational study (n=250) of CRB-701 in 2L oropharyngeal cancer; enrollment to start September 2026.
- CANYON-1 Phase 1b study of CRB-913 in obesity completed last patient visit; topline data expected September 2026.
- Appointed new CMO (Dr. Leonardo Viana Nicacio), CBO (Nishant Saxena), and Board member (Brent Pfeiffenberger).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/0001193125-26-336864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/crbp-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer